循环肿瘤DNA在胰腺癌中的临床应用进展

Advances in clinical application of circulating tumor DNA in pancreatic cancer

胰腺癌作为世界上最致命的恶性肿瘤之一,预后极差。由于缺乏特定症状,发病隐匿且发展迅速,导致大部分患者被诊断时已经处于为晚期,从而丧失有利的治疗时机。目前临床上患者多数通过影像学检查、生化检查和组织活检等方式综合诊断胰腺癌,但各有缺陷。随着近年来对肿瘤机制研究的不断深入以及液体活检技术的不断发展,循环肿瘤DNA(ctDNA)逐渐引起众人的关注,并且发挥着越来越重要的作用。笔者针对胰腺癌的早期诊断、评估预后和化疗效果、指导靶向治疗等方面,就ctDNA在胰腺癌中的临床应用进展做一综述。

Pancreatic cancer is one of the most lethal malignancies in the world,and has an extremely poor prognosis.Because of the non-specific symptoms with insidious onset and rapid development,most patients are diagnosed at an advanced stage,which deprives them of adequate treatment opportunities.At present,most patients with pancreatic cancer are diagnosed by imaging examination,biochemical examination and tissue biopsy.Each of the existing methods has its own imperfections.In recent years,with the deepening research on tumor mechanism and the development of liquid biopsy technology,circulating tumor DNA(ctDNA)has gradually attracted extensive attention and played an increasingly important role.In this review,the authors describe the clinical application of ctDNA in pancreatic cancer in terms of early diagnosis,prognosis evaluation,chemotherapy efficacy,and targeted therapy.